SAN

83.38

+1.05%↑

MRK1

117.25

-1.76%↓

SHL.DE

43.83

+1.2%↑

ARGX

756.4

-0.76%↓

FRE

47.4

-1.39%↓

SAN

83.38

+1.05%↑

MRK1

117.25

-1.76%↓

SHL.DE

43.83

+1.2%↑

ARGX

756.4

-0.76%↓

FRE

47.4

-1.39%↓

SAN

83.38

+1.05%↑

MRK1

117.25

-1.76%↓

SHL.DE

43.83

+1.2%↑

ARGX

756.4

-0.76%↓

FRE

47.4

-1.39%↓

SAN

83.38

+1.05%↑

MRK1

117.25

-1.76%↓

SHL.DE

43.83

+1.2%↑

ARGX

756.4

-0.76%↓

FRE

47.4

-1.39%↓

SAN

83.38

+1.05%↑

MRK1

117.25

-1.76%↓

SHL.DE

43.83

+1.2%↑

ARGX

756.4

-0.76%↓

FRE

47.4

-1.39%↓

Home・Aandelen Lijst・Pharming Group NV

P
Pharming Group NV

Open

1.47 -0.2

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.451

Max

1.4849999999999999

Belangrijke statistieken
By Trading Economics
Inkomsten	2.9M 7.5M
Verkoop	4.1M 97M
EPS	0.009
Winstmarge	7.758
Werknemers	404

Marktinformatie
By TradingEconomics
Marktkapitalisatie	685K 998M
Vorige openingsprijs	1.67
Vorige sluitingsprijs	1.47

Pharming Group NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 dec 2025, 23:58 UTC

Acquisities, Fusies, Overnames

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11 dec 2025, 23:56 UTC

Winsten

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11 dec 2025, 23:03 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dec 2025, 21:50 UTC

Winsten

Costco Same-Store Sales, Membership Fees Rose in 1Q

11 dec 2025, 23:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

11 dec 2025, 23:44 UTC

Marktinformatie

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11 dec 2025, 23:37 UTC

Marktinformatie

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11 dec 2025, 23:31 UTC

Winsten

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dec 2025, 22:48 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11 dec 2025, 22:35 UTC

Winsten

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11 dec 2025, 22:30 UTC

Winsten

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11 dec 2025, 22:09 UTC

Acquisities, Fusies, Overnames

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11 dec 2025, 22:05 UTC

Winsten

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dec 2025, 21:51 UTC

Acquisities, Fusies, Overnames

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

11 dec 2025, 21:39 UTC

Winsten

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11 dec 2025, 21:39 UTC

Winsten

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11 dec 2025, 21:38 UTC

Winsten

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11 dec 2025, 21:37 UTC

Winsten

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11 dec 2025, 21:37 UTC

Marktinformatie

Broadcom Sees AI Revenue Doubling -- Market Talk

11 dec 2025, 21:34 UTC

Acquisities, Fusies, Overnames

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

Dexus Aiming for Long-Term Holding of A$50M in Fund

11 dec 2025, 21:28 UTC

Marktinformatie

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Dexus: Third Party Investors to Contribute Remainder

11 dec 2025, 21:27 UTC

Acquisities, Fusies, Overnames

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11 dec 2025, 21:25 UTC

Acquisities, Fusies, Overnames

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Peer Vergelijking

Prijswijziging

Pharming Group NV Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pharming Group NV - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.